Catherine Novack

Justin Kim

Yale Jen

Kelly Shi

Marc Goodman

Yigal Nochomovitz

Sung Hong

Elaine Kim

Matthew Cross

Sung

Tom Shrader

- Aldeyra Therapeutics reported **positive results** from its Phase 2 clinical trial of **ADX-629** in alcohol-associated hepatitis, demonstrating **statistically significant improvement** in liver function markers such as MELD score, triglyceride levels, and C-Reactive Protein.  **[1341235_13d5cf24391741cc8cd2abfb105a9059_0]** 
- The company is now focusing its RASP modulator product candidate pipeline on **next-generation molecules ADX-248 and ADX-246** for dermatologic, metabolic, and retinal immune-mediated diseases.  **[1341235_13d5cf24391741cc8cd2abfb105a9059_0]** 
- Clinical development of **ADX-629 was discontinued** to prioritize the new molecules, with anticipated Investigational New Drug (IND) application filings for ADX-248 and ADX-246 updated to **2026**.  **[1341235_13d5cf24391741cc8cd2abfb105a9059_0]** **[1341235_13d5cf24391741cc8cd2abfb105a9059_1]** 
- As a result of these pipeline updates, Aldeyra's projected operational cash runway has been **extended into the second half of 2027**.  **[1341235_13d5cf24391741cc8cd2abfb105a9059_0]** **[1341235_13d5cf24391741cc8cd2abfb105a9059_1]**

Aldeyra Therapeutics Announces Positive Phase 2 Results and Pipeline Focus

- Aldeyra Therapeutics announced **positive results from a Phase 2 clinical trial** for ADX-629 in patients with alcohol-associated hepatitis, demonstrating statistically significant improvement in liver function markers such as the Model for End-Stage Liver Disease (MELD) score, triglyceride levels, and C-Reactive Protein.  **[1341235_0001193125-25-252200_aldx-ex99_1.htm:0]** **[1341235_0001193125-25-252200_aldx-20251028.htm:1]** 
- The company is **refocusing its RASP modulator product candidate pipeline** on next-generation molecules ADX-248 and ADX-246 for dermatologic, metabolic, and retinal immune-mediated diseases, and has discontinued further clinical development of ADX-629.  **[1341235_0001193125-25-252200_aldx-ex99_1.htm:0]** 
- As a result of these pipeline updates, Aldeyra Therapeutics has **extended its projected operational cash runway into the second half of 2027**.  **[1341235_0001193125-25-252200_aldx-ex99_1.htm:0]** **[1341235_0001193125-25-252200_aldx-20251028.htm:1]**

Aldeyra Therapeutics Announces Positive Phase 2 Results, Pipeline Focus, and Extended Cash Runway

Aldeyra Therapeutics (ALDX)